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Abstract
Background: Individuals with schizophrenia may have a higher risk of encounters with the criminal justice system
than the general population, but there are limited data on such encounters and their attendant costs. This study
assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost
attributable to these encounters in the one-year treatment of persons with schizophrenia.
Methods: This post-hoc analysis used data from a prospective one-year cost-effectiveness study of persons treated
with antipsychotics for schizophrenia and related disorders in the United States. Criminal justice system
involvement was assessed using the Schizophrenia Patients Outcome Research Team (PORT) client survey and the
victimization subscale of the Lehman Quality of Life Interview (QOLI). Direct cost of criminal justice system
involvement was estimated using previously reported costs per type of encounter. Patients with and without
involvement were compared on baseline characteristics and direct annual health care and criminal justice system-
related costs.
Results: Overall, 278 (46%) of 609 participants reported at least 1 criminal justice system encounter. They were
more likely to be substance users and less adherent to antipsychotics compared to participants without
involvement. The 2 most prevalent types of encounters were being a victim of a crime (67%) and being on parole
or probation (26%). The mean annual per-patient cost of involvement was $1,429, translating to 6% of total annual
direct health care costs for those with involvement (11% when excluding crime victims).
Conclusions: Criminal justice system involvement appears to be prevalent and costly for persons treated for
schizophrenia in the United States. Findings highlight the need to better understand the interface between the
mental health and the criminal justice systems and the related costs, in personal, societal, and economic terms.
Background
Individuals with severe mental illness are over-repre-
sented in the criminal justice system when compared
with the larger US population. In the United States each
year, approximately 1 million detentions in county jails
involve persons with serious mental illnesses. These
individuals are imprisoned about 8 times more fre-
quently than they are admitted to state mental hospitals
[1] and are incarcerated for significantly longer time
than other inmates [2].
Although persons with schizophrenia are known to
have a higher risk of arrest and incarceration compared
with the general population [3], many of their other
legal contacts result from being victimized by others
rather than from unlawful behavior on their part [4].
Studies of the cost of schizophrenia in the United
States have typically not included costs associated with
legal encounters [5-9], although data from non-US stu-
dies suggest that encounters with the criminal justice
system constitute a substantial proportion of indirect
costs [10,11]. One study estimated that the overall
annual (2002) US cost of schizophrenia includes $2.64
billion in direct non-health care costs for law enforce-
ment [12].
Although prior research has assessed the mental
health status of persons already incarcerated within the
criminal justice system, little is known about
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justice system, the type of legal encounters they have,
and the related direct economic cost. To that end, a
post-hoc analysis was conducted of data from a one-
year cost-effectiveness naturalistic study of patients trea-
ted with antipsychotics for schizophrenia in the United
States. That study assessed several types of encounters
the patients had with the criminal justice system, which
enabled us to identify the prevalence of such encounters,
characterize the specific types of legal encounters, esti-
mate their direct costs, compare the health care costs
between patients with and without any criminal justice
system involvement, and estimate the proportion of the
total health care cost attributable to patients’ legal
involvement.
Methods
Data source
This post-hoc analysis used data from an Eli Lilly-spon-
sored one-year multicenter, prospective, randomized
open-label cost-effectiveness study of typical and atypi-
cal antipsychotics in the treatment of schizophrenia
[13]. Patients who were 18 years or older with a DSM-
IV diagnosis of schizophrenia, schizoaffective, or schizo-
phreniform disorder and a score of 18 or more on the
Brief Psychiatric Rating Scale [14] were eligible to parti-
cipate. No patient was excluded because of involvement
with the legal system or having concurrent substance
abuse disorder or other psychiatric or medical
comorbidities.
This study was conducted at 21 sites in 15 states
between May 1998 and September 2002. The protocol
and consent procedures were approved by institutional
review boards in accordance with the Code of Ethics of
the World Medical Association (Declaration of Hel-
sinki), and after a complete description of the study was
given to the subjects, signed consent forms were
obtained from patients prior to participation in the
study. Further details about the parent study design and
methods have been published [13]. Study participants
who had at least 1 assessment of their legal encounters
were included in the current analysis. Legal encounter
information from the previous 12 months was gathered
at baseline and again at 3 post-baseline assessments at
2, 8, and 12 months (endpoint).
Measures
Patients’ baseline sociodemographic and clinical charac-
teristics were assessed using standard psychiatric mea-
sures. Sociodemographic characteristics were based on a
structured interview, the level of symptom severity was
assessed with the Positive and Negative Syndrome Scale
(PANSS) [15], and the level of functioning was assessed
using the Medical Outcome-Short Form 36 health
survey [16]. Resource utilization (e.g., hospitalizations,
use of antipsychotics) was assessed via regular and sys-
tematic abstraction of patients’ medical records with an
abstraction form developed for the study. Information
about prescribed antipsychotic medications in the 6
months prior to enrollment was used to assess prior
medication adherence level. Adherence was defined
using a customary proxy measure - the Medication Pos-
session Ratio (MPR) [17] that reflects the proportion of
days with any antipsychotic medication in the 6 months
prior to study enrollment. In addition to mean MPR
(higher is better), the proportion of patients deemed
adherent (MPR ≥80%) was also calculated in accordance
with prior research [17].
Information from 2 measures was used to assign each
participant to a group with or without criminal justice
system involvement: 1) the Schizophrenia Patient Out-
come Research Team (PORT) client survey [18] and 2)
the victimization subscale of the Lehman Quality of Life
Interview (QOLI) [19]. The PORT survey of patients’
legal involvement and the QOLI items on being a victim
of crime provided information on 11 types of encoun-
ters resulting in arrest and 7 other types of encounters
not leading to arrest. Encounters resulting in arrest
included robbery or burglary, vandalism, parole or pro-
bation violation, drug charges, forgery, weapon offense,
assault, arson, rape, prostitution, and homicide. Encoun-
ters not resulting in arrest included contempt of court,
disorderly conduct, driving while intoxicated, major
driving violations, parole or probation for at least 1 year,
being a victim of a crime, and other miscellaneous
encounters. The QOLI victimization subscale included 2
items that assessed whether the participant was a victim
of any violent crime (e.g., assault, rape, mugging, or rob-
bery) or a non-violent crime (e.g., burglary, theft, or
being cheated). This was assessed at baseline (reflecting
encounters in the past 12 months) and again at 2, 8,
and 12 months or endpoint, reflecting encounters since
the previous assessment. To correct for potentially erro-
neous repetitive participant reports of encounters with
the criminal justice system, each type of reported legal
involvement was counted only once for each participant.
However, if the patient reported having several encoun-
ters of different types, the costs of these different
encounters were added.
Cost estimates
Consistent with cost calculation in the parent cost-
effectiveness study [13], direct annual health care costs
for each participant were estimated in 2001 US dollars
using resource utilization abstracted from patients’
medical records together with Medicare data as cost
benchmarks for units of specific services. Medication
costs were based on 2001 average wholesale prices
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[13].
Since the parent study did not collect cost information
for patients’ criminal justice system encounters, the cost
of involvement was estimated using previously reported
costs per type of encounter with the legal system in a
published US study [20] and adjusted the cost to reflect
2001 US dollars to be consistent with the year in which
health care costs were estimated in the parent study. In
addition, the annual cost of probation was estimated to
be $3,236.51, based on a report by the US Office of Pro-
bation and Pretrial Services [21], adjusted to 2001
dollars.
Statistical analysis
Analyses compared participants who reported no legal
involvement with those reporting any involvement at
baseline or at any of the 3 post-baseline assessments.
Chi-square, Fisher’s exact, and t tests were used for uni-
variate comparisons of demographic, clinical, and func-
tional baseline variables. In addition to unadjusted
group comparisons on these variables, adjusted compari-
sons were conducted using a logistic regression analysis
with adjustment for age, gender, and ethnicity. Compari-
sons of mean costs between participants with versus
without criminal justice system involvement used non-
parametric bootstrapping stratified by propensity scoring
to adjust for age, gender, and ethnicity. The nonpara-
metric Wilcoxon rank-sum test was used to make uni-
variate comparisons of annual cost variables. All tests
were two-tailed at a = 0.05.
Results
Patient characteristics
Of the 651 participants, 42 were excluded from this ana-
lysis because of incomplete PORT client survey data,
leaving 609 patients. Almost all of these participants
(581 of 609, or 95%) were outpatients at baseline.
Nearly one-half of the patients (278 or 46%) reported
at least 1 legal encounter at baseline or during any post-
baseline assessment. At baseline, participants with crim-
inal justice system involvement were significantly
younger (p < .001), had a poorer level of mental health
functioning (p < .001), were more likely to have been
hospitalized in the prior year (p = .003), to use emer-
gency services (p = .021), to have a lifetime diagnosis of
substance abuse disorder (p < .001), to drink alcohol to
intoxication (p = .049), and to use cannabis and cocaine
(p < .001). They were also significantly less likely to be
adherent to antipsychotics (MPR ≥80%) (p = .001), to
have a lower mean MPR level (p < .001), and to drop
out of the one-year study (p = .020) (Table 1). Partici-
pants with any criminal justice system encounter did
not significantly differ from those without encounters
on gender, ethnicity, uninsured status, illness severity
per PANSS total score, and on physical level of func-
tioning. Following adjustment for age, gender, and eth-
nicity, results remained essentially the same on 13 of 17
key patient characteristics. The 4 variables that changed
in significance level indicated that the group with crim-
inal justice system involvement had a significantly
poorer level of physical functioning (p = .037), while 3
previously (unadjusted) significant group differences on
use of emergency services, drinking alcohol to intoxica-
tion, and study discontinuation rates became statistically
non-significant. All other group comparisons on key
characteristics were essentially unchanged.
Types of legal encounters
Among the 18 types of criminal justice system encoun-
ters assessed in this study, being a victim of crime was
the most prevalent type of involvement (67%), followed
by being on parole or probation (26%), arrest for assault
(13%), other miscellaneous encounters not resulting in
arrest (13%), being cited for a major driving violation (e.
g., reckless driving) but without arrest (11%), arrest for
parole or probation violation (10%), and being charged
with disorderly conduct (9%). All other types of encoun-
ters had a prevalence rate lower than 5% (Table 2).
Cost analyses
Overall, the mean estimated annual per-patient cost of
criminal justice system involvement was $1,429, using
2001 dollars. Compared to participants free of encoun-
ters, the annual direct health care costs for participants
with any encounter were numerically higher (but not
statistically significantly different - unadjusted and
adjusted) for total direct annual health care costs
($23,121 vs. $20,206; p = .346), with no significant cost
differences on outpatient services, medication, or labs
and other costs. The cost of inpatient hospitalization
was, however, significantly higher for participants with
any encounter ($10,330 vs. $5,376; p = .001 unadjusted,
p = .019 adjusted) (Table 3). The mean annual per-
patient cost of criminal justice system involvement
($1,429, SD = $2,676) translated to 6% of the annual
total direct health care costs for participants with invol-
vement (Table 3). Because being a victim of crime was
the most prevalent type of encounter and among the
least costly encounters, the proportion of the total cost
attributable to these encounters was also calculated after
excluding participants whose only legal encounter was
being a victim of crime (113 or 41% of participants with
any encounter). As a result, the mean annual per-parti-
cipant cost of criminal justice system involvement
increased from $1,429 to $2,386 (SD = $3,135), compris-
ing 11% (instead of 6%) of the total health care cost per
participant ($22,002, SD = $33,660).
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Considering that being a victim of crime was found to
be the most prevalent type of legal involvement in the
study (67%), it was of interest to assess differences on
key characteristics between victims of crime, perpetra-
tors (who were not victims of crime), and patients with-
out legal involvement. Patients who were both
perpetrators and victims of crime (n = 74) were
excluded from this analysis to help contrast the 3
groups. Results are presented in Table 4, showing that
differences among the 3 groups were very similar to
those found between patients with versus without legal
involvement, as victims of crime and perpetrators did
not significantly differ on any key characteristic except
one: perpetrators were significantly more likely to be
male (p = .023 unadjusted; p = .046 adjusted).
Patients with versus without legal involvement data
A small proportion of the study participants (42 of 651
or 6.5%) lacked data on the PORT, which assessed
patients’ legal involvement. We compared patients with
and without legal involvement data on key baseline
characteristics to ascertain how they might have dif-
fered. Results are presented in Table 5, showing the 2
groups significantly differed on several key characteris-
tics, with the most glaring one being that almost all
(90%) patients without PORT data have discontinued
early from the study (p < .001) with a significantly
lower treatment duration ( < .001). They were also sig-
nificantly more likely to be uninsured (p = .017), had
poorer levels of mental health functioning (p = .002),
higher use of emergency services (p = .043), more life-
time diagnosis of substance use disorder (p = .024),
and poorer levels of adherence to medication regimen
(p = .043).
Discussion
In this post-hoc analysis, about one-half (46%) of the parti-
cipants reported at least 1 encounter with the criminal jus-
tice system, with the 2 most prevalent types of encounters
being a victim of any crime (67%) and being on parole or
probation (26%). Although this study did not assess the
Table 1 Key characteristics of participants with and without legal system involvement
Variable With legal
involvement
(n = 278)
% of total
sample
Without legal
involvement (n = 331)
% of total
sample
Unadjusted p
value
Adjusted p
value
a
Age, mean ± SD, yr 41.0 ± 11.7 44.5 ± 12.1 < .001 .001
Male 180 65% 200 60% .277 .776
Ethnicity .836 .999
Caucasian 149 54% 185 56%
African-American 95 34% 109 33%
Other 34 12% 37 11%
Uninsured 57 21% 48 15% .051 .238
PANSS total score, mean ± SD 86.4 ± 18.3 86.9 ± 21.2 .770 .772
SF-36 Mental composite score
b ±
SD
-1.3 ± 1.3 -0.9 ± 1.3 < .001 .001
SF-36 Physical composite score
b ±
SD
-0.5 ± 1.1 -0.4 ± 1.0 .218 .037
Not hospitalized in the previous
year
172 64% 245 75% .003 .034
ER use in the previous 3 months 87 32% 76 24% .021 .056
Lifetime substance abuse
diagnosis
145 52% 117 35% < .001 < .001
Drink alcohol to intoxication 29 11% 19 6% .049 .088
Cannabis use 60 22% 19 6% < .001 < .001
Cocaine use 23 8% 6 2% < .001 .001
MPR ≥ 80% 92 36% 146 50% .001 .015
MPR, mean ± SD 0.5 ± 0.4 0.6 ± 0.4 < .001 .001
Discontinued study 84 30% 72 22% .020 .053
Mean days to study
discontinuation, mean ± SD
312.6 ± 93.9 325.3 ± 84.2 .082 .136
Abbreviations: ER, emergency room; MPR, medication possession ratio; PANSS, positive and negative syndrome scale; SD, standard deviation; SF-36, Medical
Outcome–Short Form 36. Possible PANSS scores range from 30 to 210, with higher scores indicating greater pathology. SF-36 standardized scores are relative to
the general population, where smaller negative scores indicate better health.
aAdjusted p value for age, gender, and ethnicity.
bWeighted averages of the Z-scores of the 8 Medical Outcome–Short Form 36 domain scores as related to general population norms.
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ters, it provides - for the first time - an estimate of the
direct economic impact of having encounters with the
criminal justice system for persons treated in the United
States for schizophrenia over a one-year period, in the
context of their total direct health care cost. This study
estimated that these encounters may comprise approxi-
mately 6% to 11% of the annual per-patient direct total
costs. While these estimated costs are applicable to per-
sons already involved with the mental health system, the
cost of encounters for persons who are not involved with
the mental health system may be substantially higher due
to multiple arrests [20] and potentially prolonged incar-
cerations. Current findings highlight the preponderance of
the interface that patients with schizophrenia have with
the criminal justice system and its economic cost, 2
important aspects that often go unreported in studies of
schizophrenia, although the link between medication non-
adherence, violent behaviors, arrests, and being a victim of
crime has been previously reported [22-25]. Our findings
are consistent with a prior US study, in which 45% of new
mental health outpatients had 1 or more criminal justice
system encounter before arriving for treatment and offen-
ders were more likely to have drug dependence, to have
greater psychological disability, and to have less personal
empowerment than other clients [26].
Also consistent with prior research [20,23-27] is our
finding that participants with any criminal justice sys-
tem encounter differed from those without encounters
on a number of characteristics. They were younger,
with a poorer level of mental health, greater likelihood
of substance abuse (alcohol, cannabis, and cocaine),
and poorer medication adherence. They were also
more likely to have inpatient hospitalizations in the
year prior to enrollment, to use emergency services,
and to drop out of the study. Although the cause-effect
relationship between medication adherence and crim-
inal justice system encounters cannot be delineated
from the current study, the findings suggest that invol-
vement may represent yet another, potentially under-
appreciated, consequence of medication nonadherence
[20,23-27].
Table 2 Types of encounters with criminal justice system, their prevalence rates, and estimated costs
Category Persons with the criminal justice system
encounter
(n = 278)
% of total
sample
Mean ± SD cost per encounter,
$
a
Crime Against the Subject
Victim of crime 187 67% 60 ± 79
Encounters resulting in arrest
On parole or probation for 1 year 73 26% 3237 ± NA
Assault 35 13% 1572 ± 1358
Parole or probation violation 27 10% 2751 ± 4820
Drug charges 11 4% 2077 ± 3817
Burglary, larceny, breaking and
entering
11 4% 2783 ± 4914
Shoplifting, vandalism 8 3% 2783 ± 4914
Weapons offense 7 3% 1599 ± NA
Robbery 5 2% 2783 ± 4914
Arson 6 2% 2751 ± 4820
Rape 4 1% 19278 ± 22463
Prostitution 2 1% 2332 ± 2518
Homicide or manslaughter 4 1% 19278 ± 22463
Forgery 2 1% 447 ± 237
Encounter not resulting in or from
arrest
Other miscellaneous encounter 36 13% 38 ± 87
Major driving violation 30 11% 1016 ± 179
Disorderly conduct 25 9% 1246 ± 896
Driving while intoxicated 6 2% 1016 ± 179
Contempt of court 6 2% 38 ± 87
aEstimated using previously reported costs per type of encounter with the legal system [20] and adjusted to 2001 US dollars.
Abbreviation: NA, not available; SD, standard deviation.
aCost per encounter was adopted from Clark and colleagues [20] and adjusted to 2001 dollars. Cost of parole or probations for 1 year was adopted from the US
Office of Probation and Pretrial Services and adjusted to 2001 dollars.
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the specific types of criminal justice system involvement
that patients with schizophrenia tend to have while
being treated in usual mental health settings across the
United States. Most prior schizophrenia studies have
not assessed this type of data. Previous studies have
examined prison populations for mental health pro-
blems. Our analysis instead evaluated patients with
mental health problems who are treated in the commu-
nity and assessed them for involvement with the crim-
inal justice system. To our knowledge, there is limited
data regarding the cost of criminal justice involvement
for patients with schizophrenia who are engaged in
mental health systems. In fact, we are aware of only one
1999 publication [20] that reported the types and costs
of these encounters. That study, by Clark and collea-
gues, included 203 persons treated for schizophrenia,
schizoaffective, and substance use disorders in New
Hampshire and used multiple data sources to estimate
the direct cost per encounter type and the total cost of
patients’ legal encounters. They concluded that poor
treatment engagement was associated with multiple
arrests and consequently greater legal costs, thus high-
lighting the importance of engaging these often reluc-
tant individuals in effective mental health treatment. To
our knowledge, the present study is the first to examine
patients with schizophrenia treated in usual care settings
and compare those with versus without criminal justice
involvement on total health care cost and cost compo-
nents (cost of inpatient hospitalization), the cost of legal
encounters, and the estimated proportion of the total
health care cost attributable to patients’ legal involve-
ment. Previous studies have examined characteristics of
mentally ill patients with versus without involvements
with the legal system [26] or examined psychopathology
in prison populations, but such studies are of a very dif-
ferent nature and orientation. For example, a recent
study of this country’s largest state prison system found
that individuals with psychiatric disorders were at
increased risk of multiple incarcerations [28]. Further-
more, because this post-hoc analysis used data of a cost-
effectiveness study in the treatment of schizophrenia, it
enabled comparison between participants with versus
without criminal justice system encounters on total
health care costs and cost components. While there
were no statistically significant group differences on
total cost and cost of outpatient services, medications,
or labs and other costs, the groups significantly differed
on inpatient hospitalization cost. The group with any
criminal justice system encounter had about twice the
inpatient hospitalization cost of those without any
encounter, pointing to differential use of the most costly
health care resources despite lack of baseline differences
in symptom severity level. These findings may reflect
the tendency of this group to be more volatile because
of substance use behaviors and medication nonadher-
ence. It is worth noting, however, that the higher hospi-
talization cost in the criminal justice system encounter
cohort was consistent with the higher rate of hospitali-
zation in the prior year compared to the group without
encounters (36% vs. 25%).
The current findings also underscore the fact that
being a crime victim is a highly preponderant phenom-
enon in this patient population, as it was reported by
about two-thirds of the study participants. The link
between schizophrenia and victimization has been pre-
viously reported and was described as 1 of 6 important
adverse outcomes that include violence, suicide/self-
harm, substance use, homelessness, and unemployment
[29]. The high rate of victimization also highlights how
susceptible these patients are to being victims of crime
because of their mental disorder and the social context
in which they live [30], as they are prone to become
prey for criminals because of their disabilities, lacking
Table 3 Annual direct health care cost and cost components for persons with versus without any criminal justice
system encounters
Mean ± SD, $
Cost category Persons with any criminal justice system
involvement
(n = 278)
Persons without any criminal justice
system involvement
(n = 331)
Unadjusted p
value
Adjusted p
value
a
Total health care
cost
23121 ± 31813 20206 ± 28307 .346 .420
Inpatient
hospitalization
10330 ± 26226 5376 ± 18525 .001 .019
Outpatient care 6890 ± 16594 8503 ± 18727 .424 .150
Medication 4704 ± 3045 5001 ± 3531 .508 .183
Labs and other
cost
1197 ± 3990 1326 ± 3272 .286 .672
Abbreviation: SD, standard deviation.
aAdjusted p-value for age, gender, and ethnicity.
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dangerous neighborhoods with high crime rates [31].
These findings suggest that patients with schizophrenia
who disclose being crime victims are likely to be at high
risk for other adverse outcomes and will require specia-
lized interventions that help address their needs,
improve their living arrangements, and increase their
engagement in the mental health system. Programs that
target these treatment needs (e.g., substance abuse, med-
ication nonadherence) in mentally ill offenders and
emphasize treatment services over incarceration of cer-
tain individuals have proven beneficial in terms of redu-
cing recidivism and overall criminal justice system
expenditures, thus potentially offsetting initial invest-
ments in these interventions [1,28,29].
The study has a number of limitations that need to be
recognized. This was a post-hoc analysis that will require
replication. The study did not collect direct cost data of
criminal justice system encounters and estimated the costs
using previously reported data. Costs of each type of
encounter with the criminal justice system were derived
exclusively from a study of dually diagnosed patients (with
substance abuse and schizophrenia, schizoaffective, or
bipolar disorders) conducted by Clark and colleagues at
New Hampshire-Dartmouth Psychiatric Research Center
[20] and adjusted to 2001 dollars. This was done because
Table 4 Key characteristics of participants without legal system involvement, participants who were only victims of
crime, and perpetrators who were not victims of crime.
Variable A
Patients without
any legal
involvement
N = 331
B
Patients who
were only
victims of crime
N = 113
C
Perpetrator who
were not victims
of crime
N=9 1
P-value
Unadjusted,
overall group
comparison
(A vs B vs C)
P-value
Adjusted for
covariates, overall
group comparison
(A vs B vs C)
P-value
Adjusted for
covariates, Victims
VS Perpetrators
(B vs C)
Age, mean (SD) 44.5 (12.1) 44.3 (11.1) 40.0 (12.0) 0.005 0.024 0.066
Male gender, n (%) 200 (60%) 57 (50%) 63 (69%) 0.023 0.046 0.016
Ethnicity –
Caucasian, n (%)
185 (56%) 69 (61%) 45 (49%) 0.566 0.646 0.333
-African-American,
n (%)
109 (33%) 33 (29%) 36 (36%)
-Other ethnic
group, n (%)
37 (11%) 11 (10%) 13 (14%)
Uninsured, n (%) 48 (15%) 13 (12%) 25 (28%) 0.006 0.132 0.074
PANSS total, mean
(SD)
86.9 (21.2) 86.9 (18.2) 84.8 (19.0) 0.659 0.648 0.482
SF36 MCS, mean
(SD)
-0.85 (1.31) -1.23 (1.33) -1.10 (1.32) 0.018 0.025 0.275
SF36 PCS, mean (SD) -0.40 (1.02) -0.55 (1.14) -0.39 (1.00) 0.372 0.366 0.990
Past year psych
hospitalization None,
n (%)
245 (75%) 79 (73%) 53 (60%) 0.016 0.167 0.714
ER past 3 months, n
(%)
76 (24%) 32 (29%) 30 (33%) 0.146 0.257 0.454
Lifetime diagnosis of
substance use
disorder, n (%)
117 (35%) 51 (45%) 45 (49%) 0.024 0.032 0.837
Use of alcohol to
intoxication, n (%)
19 (6%) 7 (6%) 9 (10%) 0.362 0.547 0.547
Any use of cannabis,
n (%)
19 (6%) 15 (13%) 20 (22%) < 0.001 < 0.001 0.466
Any use of cocaine,
n (%)
6 (2%) 4 (4%) 8 (9%) 0.005 0.018 0.242
MPR ≥ 80%, n (%) 146 (50%) 47 (46%) 28 (34%) 0.042 0.195 0.513
MPR, mean (SD) 0.60 (0.42) 0.53 (0.44) 0.42 (0.44) 0.004 0.023 0.520
Discontinued study,
n (%)
72 (22%) 30 (27%) 28 (31%) 0.170 0.294 0.820
Mean days to study
discontinuation,
mean (SD)
325.3 (84.2) 310.1 (96.0) 312.1 (99.7) 0.200 0.207 0.587
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nor are there available data for costing each type of legal
encounter across the 15 states in which our study was
conducted. This is a clear limitation of the study that ham-
pers the generalization of the findings and thereby helps
highlight the need to replicate the findings and to systema-
tically assess direct costs of legal encounters in future
research. Despite this limitation and the attendant need
for a certain degree of caution in interpreting our findings,
we are unaware of any other US study on costs of criminal
justice system encounters to serve as a foundation for the
economic analyses. Another limitation is our likely under-
estimation of the true costs associated with patients’ legal
involvements, because encounters were based on patient
self-report (often minimized) and self-report for only 19
types of encounters. In addition, it is possible that some
patients were arrested more than once for any one parti-
cular offense; however, by our protocol, these incidents
were counted only once to avoid potential erroneous repe-
tition. This methodology, together with the fact that we
captured patient self-reported victimization and its costs,
but not those of arresting or otherwise processing the
assailant, would tend to result in an underestimation of
the total costs of involvement in the criminal justice sys-
tem. Another study limitation is the paucity of information
about which encounters involved the police and which did
not, considering that some encounters (especially victimi-
z a t i o n s )a r en o tr e p o r t e dt ot h ep o l i c ea n dt h u sd on o t
incur measurable costs. Furthermore, our study consoli-
dated baseline and follow-up involvement with the crim-
inal justice system into 1 measure. However, when we
repeated our analyses using only the post-baseline data,
the findings were highly consistent with what has been
reported in this manuscript (data not shown).
Although the range of assessed encounters was broad, it
was not all-inclusive. Missing are costs associated with
federal offenses, legal fees, and other forms of involvement
with the civil court system (e.g., court commitments, guar-
dianships); domestic violence (which may be a criminal or
civil offense); criminal trespass, as well as costs associated
with arresting assailants in cases of victimization. Other
potential costs, including overtime pay for deputies on sui-
cide watch and daily incarceration costs [2] were not cap-
tured. Our analysis may have also over-corrected for
patients’ propensity toward repetitive reporting of the
same encounter over time, because we counted each
encounter only once. Although some of the participants
may have had repeated encounters during the one-year
study, our analysis did not capture them, thus potentially
further underestimating the true prevalence and resultant
cost attributable to involvement with the criminal justice
system. And lastly, the current study included only per-
sons treated for schizophrenia and related disorders at 21
treatment sites across 15 states in the United States and
did not include persons diagnosed with schizophrenia who
were in jails or prisons. The current findings are
Table 5 Key characteristics of participants with and without data on legal system involvement
Variable A
Patients with legal
involvement data
N = 609
B
Patients without legal
involvement data
N=4 2
P-value
Unadjusted, overall group
comparison
(A vs B)
Age, mean (SD) 42.9 (12.0) 41.6 (13.2) 0.480
Male gender, n (%) 380 (62%) 31 (74%) 0.185
Ethnicity – Caucasian, n (%) 334 (55%) 20 (48%) 0.533
-African-American, n (%) 204 (34%) 15 (36%)
-Other ethnic group, n (%) 71 (12%) 7 (17%)
Uninsured, n (%) 105 (18%) 13 (35%) 0.017
PANSS total, mean (SD) 86.7 (19.9) 88.2 (21.2) 0.652
SF36 MCS, mean (SD) -1.04 (1.32) -1.71 (1.34) 0.002
SF36 PCS, mean (SD) -0.44 (1.04) -0.22 (1.02) 0.189
Past year psych hospitalization: None, n (%) 417 (70%) 24 (60%) 0.216
ER past 3 months, n (%) 163 (28%) 17 (44%) 0.043
Lifetime substance use disorder diagnosis, n (%) 262 (43%) 26 (62%) 0.024
Use of alcohol to intoxication, n (%) 48 (8%) 6 (17%) 0.109
Any use of cannabis, n (%) 79 (13%) 9 (25%) 0.077
Any use of cocaine, n (%) 29 (5%) 2 (6%) 0.694
MPR ≥ 80%, n (%) 238 (44%) 11 (28%) 0.067
MPR, mean (SD) 0.53 (0.43) 0.39 (0.41) 0.043
Discontinued study, n (%) 156 (26%) 38 (90%) < 0.001
Mean days to study discontinuation, mean (SD) 319.5 (88.9) 123.5 (125.6) < 0.001
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persons diagnosed with schizophrenia.
Conclusions
Encounters with the criminal justice system are fre-
quent, costly, and perhaps underappreciated outcomes
in the treatment of persons with schizophrenia in the
United States, where being a victim of crime appears to
be the most frequent type of legal involvement. When
assessing the costs of schizophrenia, studies should
account for potential criminal justice system involve-
ment whenever possible; conversely, analyses that do
not take such expenditures into account may underesti-
mate total costs incurred by these patients in the mental
health and criminal justice systems. Future well-
designed studies that link patient-level resource utiliza-
tion data from mental health and criminal justice system
databases are needed to improve our understanding of
the interface between the mental health and criminal
justice systems, including the clinical, societal, and eco-
nomic costs of criminal justice system encounters,
among patients with schizophrenia.
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